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Inﬂammationone of the largest causes of cancer-related deaths worldwide for which there are
very limited treatment options that are currently effective. The ubiquitin–proteasome system has rapidly
become acknowledged as both critical for normal cellular function and a frequent target of de-regulation
leading to disease. This review appraises the evidence linking the ubiquitin–proteasome system with this
devastatingly intractable cancer and asks whether it may prove to be fertile ground for the development of
novel therapeutic interventions against hepatocellular carcinoma.
© 2008 Elsevier B.V. All rights reserved.1. Hepatocellular carcinoma: the problem
Hepatocellular carcinoma (HCC) is generally acknowledged as the
sixth most prevalent cancer in the world and is currently the third
most likely cause of cancer-related death worldwide [1,2]. Current
predictions suggest that the number of new cases diagnosed annually
is set to rise; in 1990, it was estimated that there were 437,000 new
cases [3] while by the year 2000, this had risen to an estimated
564,000 [4]. Globally, HCCs comprise the vast majority (N80%) of
primary, malignant liver tumours [4,5].
The incidence of primary liver cancer varies with both gender and
geographical location [4]. Rates of HCC are, on average, up to four
times higher in themale population. Geographically, age-standardised
incidence rates (ASRs; per 100,000) for the male population in Asia
vary from ∼10 in Brunei, to almost 100 in Mongolia while in Africa
rates vary from ∼1 in Malawi to nearly 80 in Mozambique. In Europe,
America and Australasia, incidence rates are consistently observed at
fewer than 10 per 100,000 (Fig. 1; [6]). Similar trends are observed, in
general, within the global female population.
Mortality from liver cancer is extremely high with many reports
quoting it as the being the thirdmost-common cause of cancer-related
death worldwide [1,2]. This high lethality is reﬂected in the
observation that it exhibits a yearly fatality ratio of approximately 1
(i.e. most cases do not survive beyond one year, post-diagnosis [4])
and only approximately 12% of cases survive to 5 years, post-diagnosis,
or beyond [7,8].
A number of established risk factors for primary liver cancer are
now known. The most signiﬁcant of these are attributable to longl rights reserved.term, persistent infection with either Hepatitis B (HBV) or Hepatitis
C (HCV) viruses, which account for approximately the 75% to 80%
of the total cases [3]. In contrast to the incidence of HBV-associated
HCC, which has remained relatively stable in recent times,
increases in the occurrence of HCC have been observed in many
so-called developed nations including Australia, America, Europe
and the U.K [9–12]. Such increases have been ascribed to the
increasing effects of long-term infection by HCV. The causes of the
observed increased HCV infection rates can be partly ascribed to
cohort effects such as those seen in Japan since the 1970s where
they were ascribed to increased HCV exposure through contami-
nated blood transfusion and needles [13] or those seen in the Nile
delta region of Egypt as a result of large scale campaigns to treat
outbreaks of schistosomal infestation [14].
Other risk factors for primary liver cancer include chronic alcohol
abuse (although it is as yet unclear whether the alcohol per se is the
cause as chronic alcoholics show a signiﬁcantly higher occurrence of
HBV or HCV antigens [15]) and exposure to key environmental toxins
such as aﬂatoxin B1 which cause speciﬁc hepatic DNA mutations [16].
In addition to primary drivers such as the Hepatitis viruses it is
increasingly apparent that chronic inﬂammation is a major contrib-
utory factor towards the development of many cancers [17] including
HCC, albeit that the precise complexities have yet to be clariﬁed. This
feature has recently been illustrated quite elegantly in a number of
transgenic animal models. One study, in which an inducible IκB
“super-repressor”was expressed, showed that functional inhibition of
NFκB activity prevented the progression of liver cancer [18] while in
contrast, a model of chemically-induced liver damage in the context of
partial NFκB inhibition led to an increased incidence of cancer [19]
and ablation of the IKKγ/NEMO subunit of the IKK complex in liver
parenchymal cells causes both steatohepatitis and liver cancer [20]. In
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stimuli and its contribution to the pathogenesis of HCC are complex
(for good recent reviews, see [21–24]). Hepatocytes lacking NFκB
activity appear to be exquisitely sensitive to apoptosis induced by
cytokines such as TNFα and the activity of NFκB is also known to
antagonise the pro-apoptotic and proliferative functions of the stress-
induced kinase, JNK. However, the liver is the one organ that stands
out by virtue of its capacity to regenerate extensively in response to
damage with surviving hepatocytes stimulated to undergo rapid
proliferation by the release of growth stimulatory cytokines (IL-6 and
HGF amongst others) from surrounding Küppfer and Stellate cells. It is
proposed that this microenvironment where hepatocytes (or their
stem-cell progenitors) are stimulated to undergo continual cell death
(in response to chronic viral infection, carcinogen exposure or other
liver injury) followed by proliferation of the surviving cells is one
where mutation is both more likely and can be passed on more
efﬁciently to daughter cells thus potentiating the development of
HCC.
The lethality of HCC is linked directly to our lack of an effective
treatment for the disease, even if diagnosis is achieved at an early
juncture. The gold standard for treatment is that of a complete liver
transplant for an early HCC exhibiting no extra-hepatic spread [25]
although the success of this procedure is restricted because of the
limiting availability of appropriate donor livers. Local surgical ablation
therapies can also prolong survival rates but frequent recurrence of
new HCC ultimately renders such treatments of limited use. There are
very limited effective chemotherapy approaches for the treatment of
HCC and even the 2007 FDA approval [26] given to the Ras/MEK/ERK
inhibitor [27], sorafenib, only increased the median survival time from
approximately eight months to ten months [28]. Other treatments
with some apparent future potential include the use of ERBB1
inhibitors such as geﬁtinib [29] and erlotinib [30] or approaches to
target the vascular endothelial growth factor system such as the use of
bevacizumab monoclonal antibody therapy [31].
As current treatments are so limited in their effectiveness,
methods for prevention of HCC are increasingly being explored. To
this end, some success has been achieved by using vaccination
programmes against HBV [32] and also by the use of interferon (IFN) to
prevent the progress towards chronic hepatitis [33,34].
The relative paucity of efﬁcacious interventions for HCC suggests
the need for new targets that may be amenable to pharmaceutical
intervention.Fig. 1. Age-standardised incidence rates (ASRs) for the occurrence of HCC in the global male
GLOBOCAN 2002 at the International Agency for Research on Cancer (IARC; http://www-de2. The ubiquitin–proteasome system
A detailed exposition of the ubiquitin–proteasome system (UPS) is
beyond the scope of this review but for good, recent reviews of the
system, the reader is directed to those by Kersher et al. [35], Pickart
and Cohen [36], Pickart and Eddins [37], Roos-Mattjus and Sistonen
[38] and Nandi et al. [39].
Brieﬂy, ubiquitin is a highly conserved 76 amino acid protein found
in all eukaryotes so far examined where it acts as a post-translational
modiﬁcation tag for other proteins (Fig. 2). Addition of ubiquitin to
target proteins is an ATP-dependent process requiring the sequential
action of three essential enzymes— E1 (ubiquitin-activating enzyme),
E2 (ubiquitin-conjugating enzyme) and E3 (ubiquitin-protein ligase
enzyme). The E3 enzyme (there are many hundreds of these in the
human genome) acts as the major substrate determining part of the
system. Ubiquitin is conjugated, mainly, to the ɛ-amino groups of
lysine residues within target proteins via its C-terminal carboxyl
group forming an iso-peptide bond. As ubiquitin itself contains seven
internal lysine residues, it follows that consecutive rounds of ubiquitin
addition can occur by addition of the incoming ubiquitin to one of the
lysine residues within the preceding ubiquitin moiety: in this way,
poly-ubiquitin chains can be built up on a target protein. If a poly-
ubiquitin chain on a target protein features linkages which are
composed via K48 of each preceding ubiquitin (a so-called K48 chain)
and the number of ubiquitin moieties is four or more, this acts as a
recognition signal for the 26S proteasome which then acts to degrade
the target protein in an ATP-dependent fashion. Ubiquitin itself is the
prototypical member of the so-called ubiquitin-like proteins (UBLs):
small post-translational modiﬁer proteins which share the β-grasp
‘ubiquitin superfold’ structure. Members of this group of proteins
share similarities in structure and many characteristics of their
activation and attachment to target proteins are analogous to that of
ubiquitin itself. The attachment to target proteins of UBLs other than
ubiquitin does not, however, usually result in target protein degrada-
tion [40].
The UPS plays a key role in many processes important for cellular
homeostasis such as regulation of the cell cycle [41], apoptosis [42–
45], receptor signalling and endocytosis [46,47] and many more. The
natural corollary of the above is the prediction that defects in one or
more of the many UPS components will be major contributory factors
to human disease; this is now widely accepted to be the case. As a
function of this, the UPS is increasingly being viewed as a novel targetpopulation expressed per 100,000. Image generated from global data accumulated for
p.iarc.fr/).
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already in clinical use particularly in the United States as an
intervention for late-stage multiple myeloma [48].
3. A role for UPS malfunction in HCC pathogenesis?
The molecular analyses of human liver cancer have highlighted
many genetic and epigenetic changes including alterations to both
oncogenes and tumour suppressor genes. A number of these genetic
modiﬁcations impinge directly upon the UPS and its function.
3.1. Gankyrin
Gankyrin is a small (25 kDa, 226 amino acids; also known as
PSMD10, 26S proteasome regulatory subunit p28 or p28GANK), highly
conserved protein containing seven ankyrin repeats [49] which was
discovered simultaneously as a subunit of the 26S proteasome [50]
which interacts speciﬁcally with the S6b ATPase [51] of the 19S
regulatory cap and via the use of subtractive cDNA cloning as a protein
which is routinely over-expressed at both themRNA and protein levels
in human HCC [52].
Available evidence suggests that gankyrin may have an early
function in HCC pathogenesis. Increased gankyrin expression in
hepatocytes occurs as one of the earliest observable events in a
chemical model of liver cancer [53] and an analysis of gankyrinFig. 2. The protein ubiquitylation cascade. Ubiquitin (Ub) is activated in an ATP-
dependent reaction by ubiquitin-activating enzyme (E1) to form a thiolester
intermediate. Activated ubiquitin is transferred, preserving the thiolester linkage, to
an ubiquitin-conjugating enzyme (E2) and is ﬁnally transferred in the presence of an
ubiquitin-protein ligase (E3) to the ɛ-amino group of a lysine residue within a target
protein via an iso-peptide bond. Multiple rounds of ubiquitin addition can subsequently
occur, each incoming ubiquitin being attached to an internal lysine of the preceding
ubiquitin moiety.expression levels in normal, cirrhotic and HCC human livers showed a
marked up-regulation in both hepatoma cell lines and in HCC samples
where expression levels were 3.6-fold higher than in cirrhotic samples
and 5.2-fold higher than para-carcinoma samples [54]. The signiﬁ-
cance of these studies linking gankyrin up-regulation to HCC
pathogenesis was elegantly demonstrated by the observation that
the use of RNAi to facilitate gankyrin knockdown in HCC resulted in
reduced cell growth, reduction in observed levels of hyper-phos-
phorylated retinoblastoma protein (pRb) and caspase 8/9-dependent
apoptosis [55,56]; the increased sensitivity of gankyrin knockdown
cells to caspase 8/9-mediated apoptosis is likely due to increased
stabilisation of the p53 tumour suppressor protein [56]. Gankyrin
expression in a rat model system of hepatic regeneration is also up-
regulated within oval cells (liver stem-cell progeny which mediate
hepatocyte proliferation in response to injury) in reaction to a
combination of chemical and partial heptectomy [57].
Initial hypotheses concerning the mechanisms of gankyrin func-
tion in HCC formationwere based around the identiﬁcation of a LxCxE
(LACDE) motif at positions 178 to 182 [52]: such LxCxE motifs are
known to function as pRb-binding motifs in both viral proteins (i.e.
HPV E7 and adenovirus E1a) and endogenous cellular proteins (i.e.
cyclin D1 or HDAC1) [58]. The LACDE motif of gankyrin was shown to
be essential for the mediating the interaction of gankyrin with pRb in
vitro and was essential for conferring anchorage-independent growth
on NIH 3T3 ﬁbroblasts [52]. The crystal structure of free gankyrin [49]
shows that the LACDE motif adopts a helical structure in contrast to
the β-strand conformation of other known pRb-interacting LxCxE
peptides and suggests that, except for Glu182, the motif is buried
within the α-helix of the ﬁfth ankyrin repeat and not accessible for
pRb-binding. Nevertheless, that the LACDE motif is essential for pRb-
binding was conﬁrmed in studies examining the interaction of
gankyrin with CDK4 [59] and the S6b ATPase [60] suggesting that
the mode of interaction must be different to that of the classical HPV
E7 LxCxE peptide.
In addition to its interaction with pRb, gankyrin has also been
shown to bind the D cyclin-dependent kinase, CDK4 [51] and in doing
so compete with p16INK4a, removing its inhibitory inﬂuence on CDK4
kinase activity [59,61]. This effect of gankyrin on CDK4 activity is
consistent with the observation that gankyrin over-expression leads
to pRb hyper-phosphorylation and release of active E2F transcription
factors [52] thereby presumably acting as a forward impetus to drive
increased cell division.
It is interesting to note greater than 80% of human HCC show a
functional disruption of the pRb/p16INK4a/cyclin D1 pathway.
Although promoter hyper-methylation and silencing of the p16INK4a
locus appears to be the most frequent alteration affecting this
pathway [62] the structural studies of Nakamura et al. [60], observed
over-expression of gankyrin in the majority of human HCC and the
interaction of gankyrin with CDK4 are all consistent with a model in
which gankyrin contributes to HCC pathogenesis by acting to ferry
hyper-phosphorylated pRb to the 26S proteasome where binding of
gankyrin to the S6b ATPase facilitates pRb release for subsequent
degradation. The effect of gankyrin binding to the S6b ATPase has yet
to be elucidated although one attractive option is that it acts to
stimulate the ATP hydrolysing activity of the ATPase in a similar
fashion to that described for the S7 ATPase on binding of the
oncoprotein, HEC [63] (Highly Expressed in Cancer cells). In so doing,
this may stimulate gating of the pore in the 20S core particle of the 26S
proteasome and facilitate the degradation of pRb.
In addition to its role affecting the pRb axis, gankyrin also impinges
upon the p53 tumour suppressor. In this context it is interesting to
note that, although it is accepted that functional p53 deﬁciency
contributes to the generation of HCC, the importance of p53 mutation
to the initial or the latter stages of HCC pathogenesis is unclear.
Evidence supporting a role for p53 mutation as a relatively late event
is apparent from experiments in transgenic mice [64].
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and it is inactivated through the action of the mdm2 (mouse double
minute-2) protein. Mdm2 is an E3 enzyme belonging to the RING-
ﬁnger family of proteins [65] that acts as a negative regulator of p53
stability through the promotion of p53 ubiquitylation and its
subsequent degradation via the 26S proteasome [66,67]. Disruption
of the p53-mdm2 interaction is a primary pathway towards the
stabilisation of p53 upon cellular stress.
Gankyrin has been shown to provide protection against chemical
agents that induce DNA damage and subsequent p53-dependent
apoptosis. In addition gankyrin interacts with mdm2 both in vitro and
in vivo, an interaction that appears to increase both the association
and activity of mdm2 for p53. This increased, gankyrin-mediated
interaction of mdm2 and p53 drives increased ubiquitylation and
subsequent proteasomal degradation of p53 [56].
A recent study by Qiu et al. [68] has highlighted both the
complexity of gankyrin interactions with p53 and pRb and the
importance of cross-talk between these two critical tumour suppres-
sors. The pRb protein can prevent the gankyrin-mediated interaction
of mdm2 and p53 thereby preventing the ubiquitylation and
subsequent degradation of p53; a function illustrated by the fact
that RNAi knockdown of pRb enhances themdm2-p53 interaction and
de-sensitises cells to DNA damage-induced apoptosis. These data are
consistent with amodel inwhich pRb can arbitrate stabilisation of p53
by disrupting the gankyrin-mediated mdm2-p53 interaction but
under conditions of increased mdm2 or gankyrin expression (such
as is often reported in cancer), pRb is degraded thus effecting an
increased degradation of p53 (Fig. 3; [68]). A detailed mechanistic
explanation of how gankyrin causes an increase in the activity of
mdm2 towards p53 must, however, await data from a co-crystal-
lographic, or similar, study.
Gankyrin appears to be a somewhat promiscuous protein; it is
known to interact with the proteasomal S6b ATPase, pRb and mdm2.
Two recent studies [69,70] have, however, implicated gankyrin in an
interaction with RelA (p65); one half of the NFκB isoform that,
together with its heterodimer partner p50, is activated via the
canonical TNFα pathway [22]. Both studies produced data that
suggests that gankyrin expression negatively regulates NFκB activity
induced by the canonical (i.e. TNFα-induced) pathway although the
mechanism(s) by which this is brought about is unknown. Chen et al.Fig. 3. Amodel for pRb regulation of gankyrin-mediatedmdm2-p53 interaction and p53
degradation (adapted from Qiu et al., 2008 [68]). Gankyrin interacts with mdm2
facilitating increased interaction of mdm2 for p53, amplifying mdm2-mediated p53
poly-ubiquitylation leading to 26S proteasome-mediated degradation of p53. pRb binds
to the central domain of mdm2 inhibiting the gankyrin–mdm2-p53 interaction thereby
stabilising p53. Conditions that lead to increased pRb degradation, such as gankyrin
over-expression or mdm2 over-expression due to copy number ampliﬁcations, or pRb
inactivation via somatic mutation can potentiate the formation of a gankyrin–mdm2-
p53 complex and p53 destabilisation.[69] suggest that gankyrin can act as a nucleo-cytoplasmic shuttling
protein which acts to shuttle NFκB from the nucleus and retain it in
the cytoplasm whereas Higashitsuji et al. [70] argue for a role of
gankyrin as an NFκB inhibitor via the action of the HDAC III enzyme,
SIRT1 and exclude a role for gankyrin as a NFκB exporting protein as
gankyrin-mediated repression of NFκB activity was unaffected by
leptomycin B, an inhibitor of CRM1-mediated nuclear export.
Although it is unclear how to reconcile the mechanistic details
presented in these studies, both point to a role for gankyrin as an
inhibitor of TNFα-induced NFκB activity. This is of interest in the
context of HCC pathogenesis as it is consistent with the recent
transgenic models [19,20] that suggest NFκB inhibition is a major
driver towards the development of primary liver cancer as NFκB
inhibition in hepatocytes causes apoptosis in many cells and leads to
compensatory proliferation favouring the accumulation of somatic
mutation. Although it remains to be elucidated, it is interesting to
speculate that gankyrin, a protein containing seven ankyrin repeats,
may function in a similar way to the classical inhibitory molecules of
NFκB signalling, the IκB proteins, of which IκBα is perhaps the most
well understood. IκBα is a target gene for NFκB and one of its
functions is to mediate the shuttling of NFκB from the nucleus to the
cytoplasm thereby decreasing NFκB activity via a negative feedback
loop [21].
3.2. HBV, HCV and the UPS
Although not part of the UPS themselves, both HBV and HCV
express a number of proteins with the potential to affect the UPS,
perhaps the best studied of which is the HBx protein of HBV. The
fourth open reading frame of the HBV genome, giving rise to a highly
conserved 16.5 kDa polypeptide, encodes the HBx protein that is
known to act as a transcriptional transactivator [71]. Amongst the
genes activated by HBx are oncogenes such as c-myc and c-fos,
components of the Ras signalling pathway and the EGF receptor. The
HBx protein is not essential for the HBV life cycle in vitro but is
required for full productive infection in vivo [72].
Amongst the cellular targets for HBx is the 26S proteasome [73,74].
HBx interacts with both the PSMC1 (S4 ATPase) and PSMA7 (α1/C2)
subunits of the proteasome by two-hybrid and immunoprecipitation
assays and co-sediments with the proteasome upon sucrose gradient
centrifugation. HBx interaction with the proteasome is required for
efﬁcient HBV replication [75]. Studies using wild-type and HBx-
negative viral strains also illustrate that HBx-negative strains replicate
at only 10% of the efﬁciency that is observed for the wild-type virus
and that inhibition of the proteasome in cells infected with HBx
deﬁcient virus restored viral replication to wild-type levels; wild-type
viral replication rates were left unaffected by proteasomal inhibition.
HBx expression in the HCC cell line, HepG2 causes a decrease in the
chymotrypsin- and trypsin-like activities of the proteasome that
suggests that HBx can act as a proteasomal inhibitor; an interesting
observation given the role of the proteasome in generating Class I
antigens for the immune system [76]. The role of HBx in immune
system evasion may also be seen in the observation that HBx can
compete with the PA28 proteasomal activator complex for binding to
the α4 subunit of the proteasome [77]. A decreased ability of PA28 to
interact with the catalytic 20S core of the proteasome would be
predicted to result in less efﬁcient Class I antigen generation [78].
HBx can also affect the stability of several oncogenes and tumour
suppressors. Co-expression of HBx with c-myc results in an increased
stability of the c-myc protein; this is effected through an interaction
between HBx and the SCF-type E3 enzyme, SCFSkp2 which causes
destabilisation of the SCFSkp2 complex [79].
Abnormal accumulation of β-catenin is a hallmark of many HCCs
and a strong positive driving force during HCC pathogenesis although
the mechanism by which β-catenin accumulation occurs is unclear. A
recent study that may shed some light on themechanistic details of β-
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to differentially regulate the levels of β-catenin via proteasomal
degradation depending on the status of cellular p53 [80]. In the
presence of p53, HBx down-regulates β-catenin via p53-dependent
transcriptional activation of the SIAH1 gene (the product of which is
the RING-ﬁnger E3 enzyme, siah1) whereas in cells lacking p53, HBx
mediates the stabilisation of β-catenin via inhibition of the glycogen
synthase-3β-dependent pathway. Many tumours with high β-catenin
expression levels exhibit high frequencies of p53 mutation that
suggests theremay be selective pressure for p53 loss in these tumours.
An intriguing recent discovery concerns the interaction of HBx
with theWD40-like repeat-containing Damaged DNA-Binding protein
(DDB1) [81,82]. DDB1 hetero-dimerises with another WD40 repeat-
containing protein DDB2 as part a CUL4-based SCF E3 enzyme
complex important for the recognition and repair of UV- and chemical
mutagen-induced DNA lesions [83,84]. Interaction of HBx with DDB1
interferes with cell viability and growth in culture, a function that has
been implicated in the establishment of infection [85] and interest-
ingly, other viral proteins also interact with the SCFDDB1 complex
during their life cycle to inﬂuence its activity and substrate range [86–
88]. Whether HBx subverts the activity of the SCFDDB1 complex to
facilitate efﬁcient HBV replication via increased or decreased
ubiquitylation activity or altered substrate speciﬁcity remains to be
determined but is intriguing nonetheless.
A characteristic of all SCF E3 complexes so far studied is that they
are regulated by the NEDD8-CAND1 cycle [89]. The cullin subunit of
SCF-type E3s is modiﬁed by the ubiquitin-like protein NEDD8, a
modiﬁcation that is generally thought to enhance the ubiquitylation
activity of the ligase by preventing the inhibitory binding to the
complex of the CAND1 protein. Removal of the NEDD8 modiﬁcation is
achieved by the action of the COP9/signalosome (CSN) complex via its
integral CSN5/Jab1 subunit, something that would be expected to
decrease the activity of the SCF ligases. However, a number of studies
have illustrated that an active CSN complex is required for optimal SCF
ligase activity, an apparent paradox that has been explained by the
need for a CSN-mediated decrease in SCF ligase activity to counter the
effects of SCF ligase autocatalytic adapter instability [90–92]. The link
between HBx and SCFDDB1 ligase complexes is further enhanced by the
observation that the CSN5/Jab1 gene in chromosomal region 8q is
often ampliﬁed in HCCs [93] and its over-expression in Hep3B cells
increases their proliferation while CSN5-speciﬁc siRNA knockdown
decreases their growth rate.
While the role of HCV gene products and their direct inﬂuence on
the pathogenesis of HCC is much less well understood than for the
HBx protein of HBV, some pertinent information has been forth-
coming. Recently, the non-structural (NS) NS5b protein of HCV that
fulﬁls the role of the viral RNA-dependent RNA polymerase has been
implicated in the degradation of the pRb tumour suppressor protein
[94,95]. The mechanism by which NS5b decreases cellular pRb levels
appears to via the restriction of pRb to the cytoplasm followed by the
recruitment of the HECT-family member E3, E6AP, leading to the
ubiquitylation and proteasomal degradation of pRb with concomitant
E2F transcription factor release and cellular proliferation. The
subversion of the E6AP ubiquitin-ligase by the NS5b protein is
reminiscent of a similar function performed by the E6 protein of
oncogenic transforming strains of the human papilloma virus in the
degradation of p53 [96].
3.3. SIAH1
Siah1 is a member of the RING-ﬁnger family of ubiquitin-protein
ligases which was originally described as a p53-induced gene up-
regulated during apoptosis [97] and recent studies have highlighted
the interaction of siah1 with the C-terminus of the Adenomatous
Polyposis Coli (APC) protein and its mediation of the β-catenin
degradation [98].The SIAH1 gene is located in chromosomal region 16q12.1, a region
that frequently undergoes loss-of-heterozygosity (LOH) during HCC
pathogenesis [99] and expression of the SIAH1 gene ismarkedly down-
regulated in advanced HCCs including those that are larger and/or
poorly differentiated [100]. However, mutational analysis of the SIAH1
gene in the same study revealed that therewere no observable somatic
mutations found in 35 HCCs studied. Presumably, therefore, other
mechanisms such as promoter hyper-methylation must be invoked to
explain the observed down-regulation of SIAH1 gene expression.
As discussed previously, siah1 is a negative regulator of β-catenin
accumulation in response to DNA damage, a function that is mediated
via activation of p53 and elevated β-catenin levels are commonly
observed in many HCCs. In HCCs that have maintained wild-type p53
function down-regulation of SIAH1 gene expression, possibly via
promoter hyper-methylation, is one possible route towards maintain-
ing or elevating β-catenin levels.
3.4. Parkin
The product of the PARK2 gene, parkin, is, like siah1, amember of the
RING-ﬁnger familyof E3enzymes. Parkindiffers fromsiah1 in its domain
organisation and contains two RING domains separated by an IBR (in-
between-RING) domain [101]; siah1 contains a single RING domain.
Parkin was originally characterised as the product of the PARK2
gene implicated in Autosomal Recessive Juvenile Parkinsonism (AR-
JP), the most frequent form of hereditary Parkinson's disease [102].
The PARK2 gene is located on chromosome 6q26 in the highly
unstable FRA6E common fragile site, a region often altered in various
solid tumours including HCCs [103] and also subject to frequent LOH
in malignant breast and ovarian tumours [104].
Evidence to support a tumour suppressive role for parkin has come
from a number of recent studies. A systematic analysis of 50 cancer-
derived cell lines including 11 fromHCCs revealed one HCC line which
contained a homozygous exon 3 deletion of the PARK2 gene, 4 of 11
HCCs containing heterozygous deletions of PARK2 exons and one with
an exon duplication [105]. Furthermore, the same study identiﬁed that
more than 50% of HCC primary tumours showed a signiﬁcant decrease
in PARK2 gene expression and parkin over-expression in HCC cell lines
slowed cell growth and rendered transfected lines sensitive to
apoptosis induced by inhibitors of the cell cycle.
A recent study using a parkin −/− transgenic mousemodel inwhich
homozygous deletion of exon 3 of the PARK2 gene was created [106]
generated mice in which hepatocyte proliferation was enhanced and
which developed hepatomegaly with increasing frequency of macro-
scopic liver tumour development at 72 and 96 weeks of age (33% and
45%, respectively). Heterozygous parkin +/− siblings showed no such
tumour development and hepatocytes from parkin −/−mice showed a
reduced susceptibility to apoptotic stimuli and a deﬁciency in caspase
activation.
The data from the above studies is consistent with parkin acting as
a tumour suppressor for the development of HCC.
Finally, the PARK2 gene shares a bidirectional promoter with an
adjacent gene, parkin co-regulated gene (PACRG). A recent study has
shown that abnormal hyper-methylation of the common PARK/PACRG
promoter is integral to decreases in parkin expression in human
leukemias [107]; such a mechanism may also function in some HCCs
where decreases in PARK2 gene expression are observed in the
absence of PARK2 somatic mutation.
3.5. NFκB signalling, the UPS and HCC
The role of chronic inﬂammation is now accepted as critical in the
pathogenesis of HCC and other cancers [17] and chronic hepatic
inﬂammation as a result of long-term infection by HBV and HCV is a
major contributory factor in cases where Hepatitis virus infection is
implicated.
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diverse immunological stimuli is mediated mainly through the
“master” regulatory transcription factor, NFκB [21,108] and much
work over the last ten to ﬁfteen years has established that the UPS
plays many and varied roles within the signalling cascades which
result in an activation of NFκB [109]. A detailed exposition of NFκB
signalling is beyond the scope of this review but the role of
ubiquitylation in the control of NFκB activation is typiﬁed by the
action of TNFα, the prototypical cytokine activator of the so-called
“classical” NFκB pathway (Fig. 4).
A number of recent studies have described defects within the NFκB
signalling system manifesting from genetic abnormalities of UPS
components correlating with HCC pathogenesis [110,111] or have
provided insight into how selective inhibition of UPS components of
NFκB signalling may provide novel and fertile targets for drug design
[112–115].
The product of the human CYLD gene is a deubiquitylating enzyme
(DUB) that was initially characterised as the gene commonly mutatedFig. 4. The “classical” NFκB signalling pathway. Trimeric TNFα binds to the TNFR1 receptor le
interaction of their respective death domains (DDs). Subsequent recruitment of RIP (recept
formation of Complex I. TRAF2 (in combination with the Ubc13/Uev1a E2 enzyme) catalys
attached to TRAF2 mediate the recruitment of the TAK1 (TGFβ-activated kinase)/TAB1 (TAK
TAB2 to the K63-linked ubiquitin chain. TRAF2 also catalyses the formation of K63-linked pol
via binding of NEMO to the K63-linked poly-ubiquitin chain. Active TAK1 subsequently cat
activation. Active IKK catalyses the phosphorylation of the inhibitory IκBα protein leading
degradation by the proteasome. This allows transport of the p50/p65 NFκB into the nucleu
proteins such as A20, cIAP1/2, the DUB enzyme CYLD and cFLIP (cellular FLICE-inhibitory pr
binding to Complex II (a TNFR1-related complex postulated to contain FADD [Fas-associated d
a DUB (via its OTU domain) removing K63-linked chains from RIP (a similar DUB activity is a
ﬁnger domains) leading to RIP degradation and repression of NFκB signalling. cIAP1/2 a
suppression of NFκB signalling. In addition cIAP1/2-mediated ubiquitylation of TRAF2 can sin the disease cylindromatosis/turban tumour syndromewhere it acts
to deubiquitylate the TRAF2 RING-ﬁnger E3 [116,117] in the classical
NFκB pathway (Fig. 4). It was also subsequently shown to deubiqui-
tylate BCL-3 [118], a member of the IκB family of NFκB inhibitory
proteins. Although an IκB member, BCL-3 appears to form transcrip-
tionally active heterodimers with both p50 and p52 [119–121] and
transgenic BCL-3 knockoutmice are unable to generate an appropriate
humoral immune response [122,123]. CYLD has subsequently also
been shown to target other proteins important in the NFκB pathway
including RIP, Lck, TAK1 and NEMO proteins [124,125].
A comparative systematic study of CYLD expression in HCC and
colon carcinoma cell lines revealed that CYLD mRNA expression is
signiﬁcantly reduced in all tumour cell lines examined [110]. In
addition, evaluation of CYLD mRNA expression levels in tumour tissue
isolated from patients in comparison with surrounding non-neoplas-
tic tissue revealed that seven (of nine) HCC and ten (of ten) colon
carcinoma samples exhibited either reduced or absent CYLD expres-
sion. Hyper-methylation as a possible cause of CYLD down-regulationading to intracellular recruitment of TRADD (TNF receptor-associated death domain) via
or-interacting protein) via its DD and TRAF2 (TNF receptor-associated factor 2) leads to
es poly-ubiquitylation, via K63 linkages of itself, RIP and NEMO. Poly-ubiquitin chains
1-binding protein 1)/TAB2 (TAK1-binding protein 2) complex via the direct binding of
y-ubiquitin chains on RIP leading to recruitment of the inactive IκB kinase (IKK) complex
alyses the direct phosphorylation of the IKK2 subunit of IKK leading to its consequent
to its K48-linked poly-ubiquitylation by the SCF E3 enzyme, SCFβ-TRCP and subsequent
s where it drives the expression of many genes including those of feedback inhibitory
otein; a catalytically inactive caspase-8 homologue). cFLIP competes with caspase-8 for
eath domain] and caspase 8; TNFR1 appears to be absent from this complex). A20 acts as
scribed to Cezanne) replacing themwith K48-linked poly-ubiquitin chains (via its zinc-
ct via their RING-ﬁnger domains to K48 poly-ubiquitylate TRAF2 and RIP leading to
uppress apoptotic signalling via Complex II.
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Additionally, there is a signiﬁcant inverse correlation between
reduced CYLD expression levels and NFκB activities measured via
luciferase reporter assays.
Interestingly, the location of the CYLD gene (chromosome 16q12.1)
falls on a region that is frequently subject to LOH during HCC
pathogenesis [99] and that also contains the SIAH1 gene that has also
been implicated in the generation of HCC.
An exciting recent discovery using cross-species comparative
oncogenomics [111] has implicated the cIAP1 protein as oncogenic
in the context of HCC pathogenesis. cIAP1 is a member of a group of
eight proteins in humans characterised by possession of one or more
baculoviral IAP (inhibitor of apoptosis) repeat (BIR) domains [126].
Interestingly, ﬁve of the eight contain a RING-ﬁnger domain
characteristic of E3s and one, BRUCE/Apollon, an enormous protein
of 4856 residues contains an ubiquitin-conjugation (UBC) domain
characteristic of E2 enzymes in addition to its single BIR domain. cIAP1
(and its close relative cIAP2) contain, in addition to multiple BIR and
RING domains, a CARD domain which is involved in apoptotic
signalling: CARD domains mediate the association of adaptor proteins
and procaspases through hetero-dimerisation of the respective
CARDs, recruiting procaspases to upstream signalling complexes and
allowing procaspase activation. The expression of at least three IAP
family members (XIAP, cIAP1 and cIAP2) occurs in response to stimuli
that activate NFκB signalling.
The study by Zender et al. [111] using a mouse model of HCC
induced by over-expression of c-myc revealed an ampliﬁed segment
in a murine chromosomal region syntenic with human chromosome
11q22. This region of human chromosome 11q harbours two genes
(cIAP and YAP1) which were subsequently conﬁrmed as oncogenic in
the context of c-myc over-expression: no oncogenic effect was seen in
the context of either H-ras or Akt over-expression highlighting that
cIAP1 oncogenicity is context-dependent. Interestingly, the authors
noticed that simultaneous over-expression of both cIAP1 and YAP1
gave a synergistic rather than additive ampliﬁcation of oncogenicity
compared with either oncogene alone.
The IAP domain-containing proteins were initially characterised as
inhibitors of the pro-apoptotic caspase enzymes [127–129] although
the exact mechanistic details, particularly for cIAP1 and cIAP2, of how
this effect is mediated is still unclear. cIAP1 can also act as an E3
enzyme for both TRAF2 and RIP leading to UPS-mediated degradation
of these proteins and down-regulation of NFκB signalling [113,130–
132] (Fig. 4) and sensitisation of cells to TNFα-induced cell killing. The
complexities surrounding the roles of the cIAPs in signalling and
cancer in also supported by recent studies of multiple myeloma (MM)
using comparative genomic hybridisation and microarray analyses
[133,134] which revealed that signiﬁcant numbers of MM patient
samples and cell lines harboured inactivating mutations in the cIAP1
and cIAP2 genes (in addition to other mutations) leading to increased,
constitutive NFκB activation. While the above data appear to suggest
contradictory roles for the cIAPs, there is much yet to be discovered
about how these proteins regulate both NFκB and apoptotic signalling
and a ﬁne balance may exist between pro- and anti-apoptotic
signalling: cIAP1 over-expressionmay favour anti-apoptotic inhibition
of the caspase-mediated cell death pathway and cell survival at the
expense of cell death.
The importance of IAPs in preventing cell death and as a potential
drug target of signiﬁcant value to HCC treatment has recently been
strikingly illustrated [112,114]. The anti-apoptotic activity of the IAP
proteins can be inhibited by natural IAP antagonists that include
Drosophila Grim, mammalian SMAC/Diablo and Omi/HtrA2 [135–137].
Mature SMAC and Omi are both mitochondrial proteins released into
the cytosol on mitochondrial outer membrane disruption during
apoptosis and interact with the BIR domain(s) of IAPs thereby
inhibiting the negative effect of IAPs on caspase activation and
allowing apoptosis to proceed [138–140]. Interaction of theseinhibitory proteins with the IAPs is mediated via conserved tetrapep-
tide motifs at the N-termini of the mature proteins that bind within a
surface groove in the IAP BIR domain(s) [140,141]. The studies by Vince
et al. [114] and Varfolomeev et al. [112] reveal that small molecule
inhibitors of IAP function manifest their ability by binding the BIR
domains of cIAP1 at the same site as the natural tetrapeptide ligands
of Grim, SMAC/Diablo and Omi/HtrA2 leading to rapid auto-
ubiquitylation and proteasome-mediated degradation of cIAP1, a
function that requires both the BIR and RING domains of cIAP1. The
loss of cIAP1 leads to activation of the classical NFκB signalling
pathway, TNFα-dependent cell death and also activates the non-
canonical NFκB signalling pathway via stabilisation of NIK, the kinase
required to activate this pathway that is normally almost undetectable
in cells.
The X-linked inhibitor of apoptosis (XIAP) protein is another
member of the IAP family, induced like cIAP1/2 in response to NFκB
activation, that has recently been identiﬁed as a target of potential
therapeutic importance to the pathogenesis of HCC [115]. Many signals
that activate NFκB also activate the JNK pathway [142,143], the
consequence of which is frequently the activation of pro-apoptotic
signals and cell death. NFκB activation circumvents these pro-apoptotic
drivers during, for example, TGFβ signalling by up-regulating the
expression of anti-apoptotic molecules such as XIAP and cIAP1/2. XIAP
is able to form a TGFβ-inducible complex with the protein kinase TAK1
that is critical for thephosphorylationandactivationof the IKKcomplex
(leading to degradation of the IκBα inhibitor of NFκB and activation of
classical NFκB signalling; Fig. 4) and MKK7, the upstream kinase
essential for activation of the JNK signalling pathway leading to
apoptosis [109]. Once bound, the RING domain of XIAP mediates the
poly-ubiquitylation of TAK1 and its subsequent degradation by the
proteasome thus ablating the activation of JNK signalling and inhibiting
apoptosis. The role of XIAP in mediating the degradation of TAK1 is
intriguing given the fact that many HCCs acquire resistance to TGFβ-
mediated cell killing, a property of normal hepatocytes. Small molecule
inhibitors of the interaction between XIAP and TAK1 may therefore
provide another potentially fertile avenue for exploration of novel,
efﬁcacious treatments for HCC.
3.6. FAT10
FAT10 is a recently characterised member of the UBL family with a
molecular weight of ~18 kDa comprising 165 amino acids. It was
originally identiﬁed as a novel gene within the genomic HLA-F locus
[144]. Based on the location of the FAT10 gene and its ability to undergo
induction of expression in response to IFNγ and TNFα [145], it was
proposed that FAT10may play a role whichmight be important for the
correct functioning of the immune system. FAT10 (along with UCRP/
ISG15) is unusual amongst UBL proteins in that it is composed of two
tandem, head-to-tail β-grasp ubiquitin superfolds [35,40]. At the level
of primary sequence the N-terminal UBL domain is ~30% identical
while the C-terminal UBL domain is ~35% identical to ubiquitin itself.
In common with ubiquitin and most of the other UBL proteins, FAT10
contains the conserved Gly-Gly di-peptide at its C-terminus, a feature
that is essential for the formation of iso-peptide bonds with ɛ-amino
groups of lysine side chains within target proteins [146] and FAT10 has
been observed to form conjugates with target proteins that may play a
role in promoting apoptosis [147]. Interestingly, there is also a
conserved lysine residue within the FAT10 sequence analogous to the
K48 of ubiquitin raising the possibility of FAT10 chain formation or
possibly modiﬁcation by ubiquitin or other UBLs.
Recently, several reports have linked FAT10 over-expression with
the development of HCC in humans [148–150]. Northern blot analyses
for FAT10 mRNA expression in 23 patient HCC samples revealed that
there was a signiﬁcant up-regulation of FAT10 expression in 90% of
patients. This datawas substantiated by the use of in situ hybridisation
and immunohistochemistry using anti-FAT10 antibodies revealed the
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hepatocytes and not the surrounding non-HCC or immune cells [148].
A more recent study of FAT10 expression in HCC and colon cancer cells
[150] revealed that FAT10 expression was induced up to 100-fold by
the synergistic action of both IFNγ and TNFα. Experiments investigat-
ing whether FAT10 itself is an oncogene revealed however that it is
incapable of transforming NIH3T3 cells, a property of many genuine
oncogenes such as H-ras.
A study by Oliva et al. [149] also revealed an almost 200-fold
increase in FAT10 expression through the use of the drug 3,5-
diethoxycarbonyl-1,4-dihydrocollidine (DDC), a compound which
induces the formation of Mallory–Denk Bodies (MDBs) in the liver:
chronic liver disease which includes the presence of MDBs is
associated with the later formation of HCC [151–153]. The increase
in FAT10 expression in this model appears to be due to epigenetic
alterations as animals re-fed S-adenosylmethionine showed no FAT10
expression increases. The results of these studies suggest that FAT10
may be important for HCC pathogenesis itself and may also provide a
good marker for the identiﬁcation of liver pre-neoplasia.
4. Conclusions
The global problem of hepatocellular carcinoma is signiﬁcant with
frequently poor prognoses and short life expectancies post-diagnosis
combined with current treatment options that are often ineffective.
New avenues are therefore required to develop more effective
treatments and drug regimens.
Twenty-ﬁve years ago, the UPS was unheard of outside a few
dedicated enthusiasts. In the intervening years we have discovered
that the UPS is critical for normal homeostasis in every cell and the
importance of its de-regulation is becoming increasingly apparent to a
myriad of disease processes from neurodegeneration to cancer. The
ﬁrst speciﬁcally designed drug (bortezomib) that affects the UPS is
showing promise in the clinical setting even though it is effectively a
fairly crude broadsword with which to tackle disease. Second and
third generation molecules that selectively target speciﬁc E3 or DUB
enzymes are already in development and should provide more of a
rapier to speciﬁcally target only the key enzyme critical for effective
therapeutic intervention.
The increasing evidence of multiple roles for the UPS within the
pathogenesis of HCC suggests that it may prove to be fertile ground on
which to develop novel therapies that will prove effective in the
treatment of this most devastating disease.
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